

ATGC BioPharm and Omnia Biologics to Collaborate on Manufacturing of Novel Therapeutic Biopharmaceuticals



April 13 2005 ATGC BioPharm and Omnia Biologics to Collaborate on manufacturing of Novel Therapeutic biopharmaceuticals Baltimore MD April 11 2005 - ATGC BioPharm announced that it has signed an agreement with Omnia Biologics Inc to collaborate on the development of manufacturing technologies by applying ATGC BioPharm's proprietary Electronic Eye technology Through this collaboration we intend to leverage the skills and strengths of both companies to manufacture biopharmaceutical products for important clinical indications where there is significant unmet medical need said Louis Cantolupo Omnia's Director of Business Development We are excited about the potential of this collaborative agreement with ATGC BioPharm Bio manufacturing is clearly one of our core technologies in custom manufacturing said Dr Dale VanderPutten CEO of Omnia Biologics As this field is rapidly developing and expanding we expect that this relationship with ATGC BioPharm will further leverage our leading position in biomanufacturing For us quality assured manufacturing is one of the knowledge based solutions that we can offer to the benefit of our customers This collaboration provides ATGC BioPharm with yet another opportunity to leverage our expertise in developing Quality By Design manufacturing technologies stated Arkesh Mehta ATGC BioPharm's CEO We are pleased to add Omnia Biologics to our growing list of partners and look forward to working with them to improve the manufacturing of biopharmaceutical products Harry Brubaker ATGC BioPharm's vice president of Business Development added This collaboration complements and extends our internal strategy to develop superior products in the area of gene and proteinbased therapeutics This manufacturing partnership with Omnia provides ATGC BioPharm with extensive product manufacturing capacity and globally competitive cost of goods for our growing range of biopharmaceutical products Omnia's state of the art Bio safety level3 facility meets all of our requirements for production including cost capacity quality and flexibility said Arkesh Mehta Most importantly Omnia has consistently demonstrated their capabilities and expertise in jointly scaling up the pilotscale processes developed by ATGC BioPharm using its proprietary manufacturing hosts and protocols The collaboration between our teams has consistently resulted in superior production yields which is essential for the costcompetitiveness of products we manufacture About ATGC BioPharm's Electronic Eye Platform ATGC Electronic Eye is a self monitoring closed loop technology that uses noninvasive and nondestructive near infrared and acoustooptical sensors to monitor the manufacturing process in realtime Combined with highthroughput process development platform these patentpending technologies yield a complete picture of the detailed functional behavior of every biopharmaceutical product About ATGC BioPharm ATGC BioPharm is a leader in applying proprietary Quality by Design technologies for the rapid manufacturing and optimization of novel biopharmaceutical products The Company is directing its integrated portfolio of technologies to the process development and production of commercially valuable molecules with agricultural biotechnological chemical industrial and pharmaceutical applications ATGC BioPharm has established alliances and joint ventures with market leaders such as Avanti Therapeutics Blumberg Associates BPI Technologies and CBTEK In addition the Company has formed a broad strategic relationship with Avanti Therapeutics a leading personalized medicine platform company ATGC BioPharm has commercialized products both independently

and in collaboration with strategic partners and licensees Additional information is available at ATGC BioPharms website www.biopharmatg.com About Omnia Biologics www.omniabiologics.com Omnia Biologics Omnia is a contract manufacturer focused on the development of innovative biopharmaceutical platforms and technologies Omnia offers services in the areas of process development GMP manufacture and fill/finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols These include autologous therapeutics new gene therapeutic platforms and stem cell technologies The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world Note Electronic Eye Quality By Design are trademarks of ATGC BioPharm Contact ATGC BioPharm Jenny Smith Corporate Development Investor Relations WWW.biopharmatg.com email protected from spam bots 301 5405474 Omnia Biologics Louis Cantolupo Director Business Development Tel 3019845928 email protected from spam bots